Medgenics Inc (NASDAQ:GNMX) – Stock analysts at Zacks Investment Research issued their Q1 2018 earnings per share estimates for shares of Medgenics in a report issued on Wednesday. Zacks Investment Research analyst B. Marckx expects that the biotechnology company will earn ($0.14) per share for the quarter. Zacks Investment Research also issued estimates for Medgenics’ Q2 2018 earnings at ($0.15) EPS, Q3 2018 earnings at ($0.15) EPS, Q4 2018 earnings at ($0.14) EPS, FY2018 earnings at ($0.58) EPS, FY2019 earnings at ($0.57) EPS and FY2020 earnings at ($0.51) EPS.
Shares of Medgenics (NASDAQ GNMX) opened at $2.11 on Monday. Medgenics has a 52 week low of $0.98 and a 52 week high of $2.65. The firm has a market capitalization of $125.20, a P/E ratio of -2.43 and a beta of 1.06.
WARNING: “Medgenics Inc (GNMX) Expected to Earn Q1 2018 Earnings of ($0.14) Per Share” was published by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3300642/medgenics-inc-gnmx-expected-to-earn-q1-2018-earnings-of-0-14-per-share.html.
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn's disease.
Receive News & Ratings for Medgenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics and related companies with MarketBeat.com's FREE daily email newsletter.